Side-by-side comparison of AI visibility scores, market position, and capabilities
SF no-code computational biology API democratizing AlphaFold and protein engineering tools for pharma and biotech; YC W24 $14.1M with $13.6M Series A May 2025 serving thousands of researchers without bioinformatics infrastructure.
Tamarind Bio is a San Francisco-based computational biology platform — backed by Y Combinator (W24) with $14.1 million raised including a $500,000 seed in 2024 and a $13.6 million Series A in May 2025 — providing pharmaceutical companies, biotechs, and academic researchers with no-code API access to advanced computational biology tools (AlphaFold protein structure prediction, antibody engineering models, protein-protein interaction prediction, molecular dynamics simulation) that historically required high-performance computing infrastructure, specialized bioinformatics expertise, and weeks of computational time to run. Founded in 2023 with a 7-person team, Tamarind serves thousands of researchers across large pharma companies, biotech startups, and academic institutions that need computational biology capabilities without building or maintaining HPC infrastructure.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.